Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction

참고문헌 (40)

1. International Diabetes Federation, "IDF Diabetes Atlas" (2021), International Diabetes Federation
2. McMurray, J. J. V., "Heart failure : a cardiovascular outcome in diabetes that can no longer be ignored", Lancet Diabetes Endocrinol, 2, pp.843~851 (2014)
3. Holman, R. R., "10-year followup of intensive glucose control in type 2 diabetes", N. Engl. J. Med, 359, pp.1577~1589 (2008)
4. Rorth, R., "Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction", Diabetes Care, 41, pp.1285~1291 (2018)
5. Kong, M. G., "Impact of diabetes mellitus on mortality in patients with acute heart failure : a prospective cohort study", Cardiovasc. Diabetol, 19, pp.49~ (2020)
6. Jang, S. Y., "Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus", Cardiovasc. Diabetol, 20, pp.180~ (2021)
7. "Guidance for Industry Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 8", ~ (2008)
8. Zinman, B., "Empagliflozin, cardiovascular outcomes, and mortality in type 2diabetes", N. Engl. J. Med, 373, pp.2117~2128 (2015)
9. Wiviott, S. D., "The design and rationale for the Dapagliflozin Effect on Cardiovascular Events(DECLARE)-TIMI 58 Trial", Am. Heart J, 200, pp.83~89 (2018)
10. Bhatt, D. L., "Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure", N. Engl. J. Med, 384, pp.117~128 (2021)
11. Chao, E. C., "SGLT2 inhibition-a novel strategy for diabetes treatment", Nat. Rev. Drug Discov, 9, pp.551~559 (2010)
12. Uhlen, M., "Proteomics. Tissue-based map of the human proteome", Science, 347, pp.1260419~ (2015)
13. Turk, E., "Glucose", galactose malabsorption caused by a defect in the Na+, Nature, pp.1991, 350[DOI]
14. Zambrowicz, B., "LX4211, a dual SGLT1", SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial, 2012, pp.92, 158~169
15. Uthman, L., "Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts : inhibition of Na(+)", H(+)exchanger, lowering of cytosolic Na(+)and vasodilation, 2018, pp.61, 722~726
16. Zuurbier, C. J., "Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na +", H+ exchanger 1 : persistent inhibition under various experimental conditions, 2021, pp.117, 2699~2701
17. i in the heart, "Cardiovasc. Res", 2021, 2794~2806
18. Trum, M., "Empagliflozin inhibits Na(+)", H(+)exchanger activity in human atrial cardiomyocytes, 2020, pp.7, 4429~4437
19. Kilić, A., "Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation", J. Pharmacol. Exp. Ther, 351, pp.492~499 (2014)
20. Inho Kim, "Development of a Zebrafish Larvae Model for Diabetic Heart Failure With Reduced Ejection Fraction", Korean Circulation Journal, 53(1), pp.34~46 (2023), 대한심장학회[DOI]
21. Choi Tae-Young, "Zebrafish as an animal model for biomedical research", Experimental and Molecular Medicine, 53, pp.1~8 (2021), 생화학분자생물학회[DOI]
22. Huang, C. J., "Germ-line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish", Dev. Dyn, 228, pp.30~40 (2003)
23. National Research Council, "Guide for the Care and use of Laboratory Animals" (2011), The National Academies Press
24. AVMA (American Veterinary Medical Association), "AVMA guidelines for the euthanasia of animals" (2020), American Veterinary Medical Association
25. 구교정, "Zebrafish Larvae Model of Dilated Cardiomyopathy Induced by Terfenadine", Korean Circulation Journal, 47(6), pp.960~969 (2017), 대한심장학회[DOI]
26. 전혜련, "Fimasartan, an angiotensin II receptor antagonist, ameliorates an in vivo zebrafish model of heart failure", The Korean Journal of Internal Medicine, 35(6), pp.1400~1410 (2020), 대한내과학회[DOI]
27. Varadi, M., "AlphaFold Protein Structure Database : massively expanding the structural coverage of protein-sequence space with high-accuracy models", Nucleic Acids Res, 50, pp.D439~D444 (2022)
28. Trott, O., "AutoDock Vina : improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading", J. Comput. Chem, 31, pp.455~461 (2010)
29. Lomenick, B., "Target identification using drug affinity responsive target stability(DARTS)", Proc. Natl. Acad. Sci. USA, 106, pp.21984~21989 (2009)
30. Bresciani, E., "An efficient dissociation protocol for generation of single cell suspension from zebrafish embryos and larvae", MethodsX, 5, pp.1287~1290 (2018)
31. Nakamura, T. Y., "Activation of Na+", H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure, 2008, pp.103, 891~899
32. Grempler, R., "Empagliflozin, a novel selective sodium glucose cotransporter-2(SGLT-2)inhibitor : characterisation and comparison with other SGLT-2 inhibitors", Diabetes Obes. Metab, 14, pp.83~90 (2012)
33. Young, S. L., "Sotagliflozin, a dual SGLT1", 2 inhibitor, improves cardiac outcomes in a normoglycemic mouse model of cardiac pressure overload, 2021, pp.12, 738594~
34. Zhou, L., "Human cardiomyocytes express high level of Na+", glucose cotransporter 1(SGLT1), 2003, pp.90, 339~346
35. Banerjee, S. K., "SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states", Cardiovasc. Res, 84, pp.111~118 (2009)
36. Matsushita, N., "Chronic pressure overload induces cardiac hypertrophy and fibrosis via increases in SGLT1 and IL-18 gene expression in mice", Int. Heart J, 59, pp.1123~1133 (2018)
37. Kadowaki, T., "Empagliflozin monotherapy in Japanese patients with type 2diabetes mellitus : a randomized, 12-week, double-blind, placebo-controlled, phase II trial", Adv. Ther, 31, pp.621~638 (2014)
38. Lapuerta, P., "Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy", Clin. Cardiol, 36, pp.367~371 (2013)
39. Zheng, W., "Comparative transcriptome analyses indicate molecular homology of zebrafish swimbladder and mammalian lung", PLoS ONE, 6, pp.e24019~ (2011)
40. Jandeleit-Dahm, K., "Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+)exchange and prevented by Na(+)-H(+)exchange inhibition", Circ. Res, 87, pp.1133~1140 (2000)

관련 논문AI추천